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ABSTRACT
Background. Survival for pancreatic ductal adenocarci-
noma is low, the role of adjuvant therapy remains
controversial, and recent data suggest adjuvant chemora-
diation (CRT) may decrease survival compared with
surgery alone. Our goal was to examine efﬁcacy of adju-
vant CRT in resected pancreatic adenocarcinoma compared
with surgery alone.
Materials and Methods. Patients with pancreatic adeno-
carcinomaatJohnsHopkinsHospital(n = 794,1993–2005)
and Mayo Clinic (n = 478, 1985–2005) following resection
who were observed (n = 509) or received adjuvant 5-FU
based CRT (median dose 50.4 Gy; n = 583) were included.
Cox survival and propensity score analyses assessed asso-
ciations with overall survival. Matched-pair analysis by
treatment group (1:1) based on institution, age, sex, tumor
size/stage, differentiation, margin, and node positivity with
N = 496 (n = 248 per treatment arm) was performed.
Results. Median survival was 18.8 months. Overall sur-
vival (OS) was longer among recipients of CRT versus
surgery alone (median survival 21.1 vs. 15.5 months,
P\.001; 2- and 5-year OS 44.7 vs. 34.6%; 22.3 vs. 16.1%,
P\.001). Compared with surgery alone, adjuvant CRT
improved survival in propensity score analysis for all
patients by 33% (P\.001), with improved survival when
stratiﬁed by age, margin, node, and T-stage (RR = 0.57–
0.75, P\.05). Matched-pair analysis demonstrated OS was
longer with CRT (21.9 vs. 14.3 months median survival; 2-
and 5-year OS 45.5 vs. 31.4%; 25.4 vs. 12.2%, P\.001).
Conclusions. Adjuvant CRT is associated with improved
survival after pancreaticoduodenectomy. Adjuvant CRT
was not associated with decreased survival in any risk
group, even in propensity score and matched-pair analyses.
Further studies evaluating adjuvant chemotherapy com-
pared with adjuvant chemoradiation are needed to
determine the most effective combination of systemic and
local–regional therapy to achieve optimal survival results.
INTRODUCTION
Annually, approximately 42,000 cases of pancreatic
cancer are diagnosed in the United States, with about
35,000 attributable cancer-related deaths each year.
1 Most
patients with pancreatic adenocarcinoma present with
advanced disease, precluding curative therapy. While sur-
gical resection is the only curative modality for those with
localized disease, only 10%–15% of pancreatic adenocar-
cinoma patients are resectable at presentation.
2–5
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denectomy (PD) with curative intent is less than 20%.
4–6
Both local and systemic relapses are common following
PD or total pancreatectomy, suggesting systemic and local
adjuvant therapy are necessary to improve outcomes.
7
In an effort to improve both local control and overall
survival following resection, the efﬁcacy of adjuvant che-
moradiation (CRT) and chemotherapy have been evaluated
in several trials. The Gastrointestinal Tumor Study Group
(GITSG) ﬁndings support the use of adjuvant CRT, while
the European Organisation for Research and Treatment of
Cancer (EORTC) trials suggested beneﬁt.
8–10 However,
clinical trial outcomes from the European Study Group for
Pancreatic Cancer (ESPAC-1) suggested a detrimental
effect on survival compared with adjuvant chemotherapy or
surgery alone.
11,12 Despite many concerns raised regarding
study design, radiation administration, and quality control
of the study,
13–18 conclusions drawn from the ESPAC-1
trial have raised doubts about the implementation of adju-
vant CRT for pancreatic adenocarcinoma in spite of other
data showing efﬁcacy of adjuvant or neoadjuvant CRT for
other gastrointestinal cancer sites.
19,20 Recently, several
single institution retrospective and prospective studies have
demonstrated the utility of adjuvant CRT compared with
surgery alone, with adjuvant CRT outcomes similar to those
of a recent randomized trial evaluating gemcitabine versus
ﬂuorouracil chemotherapy for adjuvant CRT.
21–24 How-
ever, compared with randomized trials, retrospective
studies frequently are plagued with concerns of bias asso-
ciated with the nonrandom allocation of patients to adjuvant
treatment modalities or observation.
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The goal of this study was to combine the experiences of
two major academic institutions that treat high volumes of
patients with pancreatic adenocarcinoma to examine the
efﬁcacy of adjuvant CRT. This study proposed to: (1)
determine factors that predict survival following PD, (2)
examine the beneﬁt of adjuvant CRT by risk group, and (3)
account for biases associated with treatment selection of
adjuvant CRT in retrospective data through propensity
score analysis and matched-pair analysis.
METHODS
Study Design and Participants
Thisstudywasapprovedbytheinstitutionalreviewboards
of the Mayo Clinic, Rochester, and the Johns Hopkins Hos-
pital. Study participants were drawn from all patients who
underwent pancreaticoduodenectomy (PD) for pancreatic
canceratthe Johns Hopkins Hospitalbetween 1993and2005
(n = 794, prospectively collected) and the Mayo Clinic,
Rochester, from 1985 to 2005 (n = 592, retrospectively
collected). Of the 1386 patients, individuals were excluded
who diedwithin 60 daysof surgery, had unresectable disease
(T4 or M1), periampullary tumors, received intraoperative
radiation therapy or experimental pancreatic cancer vaccine
therapy, had distal pancreatectomies, single modality adju-
vant treatment, or were missing data on margin status, nodal
status, or histologic grade (n = 294).
Surgery
Patients underwent either a pylorus-preserving, classic,
or total PD. A pylorus-preserving PD included resection of
the head and uncinate process of the pancreas, distal bile
duct, all but the most proximal duodenum, and gallbladder,
when present. A classic PD also included the antrum of the
stomach. A total PD included the entire pancreas with the
spleen. Lymph nodes were considered positive if any
lymph node in the resection specimen contained metastatic
carcinoma, whether it was involved by direct extension or
was contiguous with the primary tumor. Resection margins
were considered positive if the carcinoma was close
(within 1 mm) or present at the ﬁnal pancreatic neck,
uncinate process, bile duct, duodenal, or retroperitoneal
soft tissue margin. All pathology specimens were reviewed
by either a single pathologist at JHH or centrally at the
Mayo Clinic. Variables included in analyses for which we
had information for all study participants were age, gender,
surgery type, year of surgery, surgical margin, nodal status,
and histologic grade. T-stage was unknown for 16.6%
(n = 181) of participants, all from JHH. Race, comorbid
diseases (diabetes, cardiovascular disease, chronic
obstructive pulmonary disease, hypertension), and opera-
tive characteristics (surgical complications, vascular
invasion, perineural invasion) were available for a signiﬁ-
cant portion of patients from JHH but not the Mayo Clinic
and were not included in analyses. Patient follow-up
information was obtained from hard-copy and electronic
hospital charts. Survival was determined and cross checked
by review of clinical follow-up information, cancer center
abstracting services, or the Social Security Death Index.
Adjuvant CRT
Of the 1,092 patients who underwent resection with
curative intent and met the inclusion criteria, 56.6%
(n = 618) were from JHH and 43.4% (n = 474) from the
Mayo Clinic. Median follow-up for the total study was
18.2 months. Of the 1,092 patients, 509 (46.6%) received
surgery alone, without any adjuvant therapy. When strati-
ﬁed by adjuvant treatment, survival did not signiﬁcantly
differ by institution (P[.35, results not shown). Patients
who underwent PD with adjuvant CRT (n = 583) received
5-ﬂuorouracil (FU) based adjuvant CT, with 98% of Mayo
982 C. C. Hsu et al.Clinic adjuvant CRT patients receiving concurrent 5-FU
based CT while JHH patients were offered continuous
infusion FU with RT followed by maintenance FU for an
additional 2–6 months. Of adjuvant CRT patients who
underwent PD at JHH, 50.4% received adjuvant therapy at
JHH and 49.6% were treated elsewhere, with similar rec-
ommendations forCRTpriortodischarge.Ofadjuvant CRT
patients whounderwentresectionatthe Mayo Clinic, 51.5%
received adjuvant CRT at the Mayo Clinic and 48.5% else-
where. There was no statistically signiﬁcant difference in
survival between the four groups who underwent PD at JHH
and received adjuvant CRT at JHH, PD at JHH and adjuvant
CRT at an outside facility, PD at Mayo Clinic and adjuvant
CRTattheMayoClinic,andPDatMayoClinicandadjuvant
CRT atan outside facility (P = .35). The details ofadjuvant
radiotherapyhave beendescribedindetailelsewhere.
22,23In
brief, adjuvant external-beam RT was delivered with linear
acceleratorsusingmultiple-ﬁeldtechniques,withthemedian
RT dose of 50.4 Gy and daily fraction of 1.8 Gy. The
majorityofpatientsreceivedacontinuouscourseofradiation
therapy without a planned break.
Statistical Analysis
Statistical analyses were performed using STATA,
version 9 (Stata, College Station, TX). Summary statistics
for continuous and dichotomous variables are provided.
Tests of differences were performed using t tests and v
2
tests. For analyses stratiﬁed by T stage, v
2 tests and anal-
yses were performed including only those with known
status, as indicated. The primary outcome variable was OS,
deﬁned as the time from surgical resection for pancreatic
cancer to death, as described previously.
22,23 Survival
curves were estimated using Kaplan–Meier techniques.
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Comparisons of OS between groups were made using the
log-rank test. Median OS (in months) with 95% conﬁdence
intervals (95% CI) was estimated within each risk group
and by adjuvant treatment. The proportion of individuals
surviving up to 2 and 5 years was calculated using life
tables, with comparison by adjuvant treatment performed
using the log-rank test with survival time censored at 2 and
5 years, respectively.
Proportional hazards models were used to examine the
association with mortality of adjuvant treatment and other
patient characteristics.
27 Univariate analyses were used to
examine individual risk factors and associations with mor-
tality. To examine the independent association of adjuvant
therapy and OS after surgical resection, multivariate analy-
seswereperformedadjustingforconfounders,includingage
C70 (yes vs. no), sex, institution, margin positivity, node
positivity, tumor differentiation (G1/2 vs. G3/4), surgery
type, and T-stage. Data on postoperative recovery, perfor-
mance status, and CA 19-9 were either unavailable or
insufﬁcient, not allowing for informative analyses. Among
all patients, T-stage was missing from 181 JHH patients.
Multivariatemodelsthatincluded(n = 1,092)andexcluded
(n = 911) those with missing T-stage were comparable
(results not shown), and these individuals were included in
our ﬁnal analyses. To further examine the association of
mortality with adjuvant CRT compared with surgery alone,
we also stratiﬁed by risk factors associated with mortality.
To account for biases in treatment effect arising from
nonrandom allocation of patients to treatment groups,
propensity score analyses were performed.
28 A propensity
score was generated using 16 variables, including age,
gender, surgery type, year of surgery, surgical margin, node
status, histologic grade, T-stage, race, diabetes, cardio-
vascular disease, chronic obstructive pulmonary disease,
hypertension, surgical complications, vascular invasion,
and perineural invasion of the tumor. Those missing
information for variables were coded as a separate category
such that a propensity score was generated for all partici-
pants. Propensity score analysis required calculation of the
conditional probabilities for the two treatment groups
(adjuvant CRT vs. surgery alone) using multivariate
regression, generating a propensity score, which was used
in multivariate Cox regression model.
28 For the propensity
score, the receiver operating curve area under the
curve = 0.74, and 68.4% of patients were correctly clas-
siﬁed to treatment according to the multivariate model.
To further account for treatment selection biases asso-
ciated with retrospective data, 1-to-1 matching by
treatment group was performed (adjuvant CRT and surgery
alone). Individuals were matched on institution, age group,
sex, surgery type, tumor size (JHH), tumor stage (Mayo
Clinic), tumor differentiation, margin status, and nodal
status. In total, there were 496 patients in this analysis
(n = 248 adjuvant CRT and n = 248 surgery alone). Of
this group, 228 were from Hopkins and 268 from Mayo
Clinic, Rochester. Individuals did not differ signiﬁcantly
by treatment group for any of the matched characteristics.
Unadjusted and stratiﬁed Cox proportional hazards analy-
ses were performed.
RESULTS
Clinical Characteristics of Study Population, by
Adjuvant Treatment Group
As shown in Table 1, compared with those who under-
went surgery without adjuvant therapy, patients who
received adjuvant CRT were younger at time of treatment
(median age 70.2 vs. 64.7 years, P\.001), had worse
histology (grade 3 or 4: 51% vs. 59%, P = .019), and had
more margin positive disease (31% vs. 35%, P\.001).
Adjuvant Chemoradiation for Pancreatic Cancer 983Gender, surgery type, tumor stage, and nodal status were
not associated with the type of adjuvant treatment.
Clinical and Treatment Characteristics Associated
with Overall Mortality
In the 1,092 patients in the study population, median
follow-up was 18.2 months. Median overall survival was
18.8 months (95% CI: 17.7–20.0), with 2-year and 5-year
overall survival of 40.0 and 19.4%. As shown in Table 2,
those who were C70 years had a 20% increase in mortality
compared with those\70 years of age (median OS 17.5 vs.
19.7 months, P = .008). T3 stage, poor histological dif-
ferentiation, node positivity, and margin positivity each
increased risk of death by approximately 45% compared
with those without the respective risk characteristic (RR
range 1.44–1.47, all P\.001). Gender and surgery type
were not associated with mortality differences. As illus-
trated in Fig. 1, compared with those who underwent
surgery alone, adjuvant CRT improved survival with a RR
of 0.73 (95% CI: 0.64–0.84) with longer median OS (15.5
vs. 21.1 months) and greater 2-year (34.6 vs. 44.7%) and 5-
year survival (16.1 vs. 22.3%), respectively (P\.001).
Associations of Adjuvant CRT with Overall Mortality,
Overall, and by Risk Group
In Table 3, adjustments were made for known and
potential confounders, including age, gender, institution,
surgery type, tumor stage, margin status, node status, and
tumor differentiation, and a propensity score was included
in the multivariate model to further adjust for potential bias
associated with treatment selection. The results demon-
strated that compared with surgery alone, adjuvant CRT
signiﬁcantly decreased risk of mortality in the study pop-
ulation with an adjusted RR of 0.67 (95% CI: 0.58–0.78,
P\.001, Table 3). Data were further stratiﬁed by known
clinical predictors of mortality, and among each risk group,
adjuvant CRT was protective (adjusted RR range: 0.56–
0.83) and statistically signiﬁcant in all groups, except those
with tumor stage 1–2 (adjusted RR 0.83, 95% CI: 0.66–
1.03, P = .087).
Matched-Pair Analysis
To further attempt to account for treatment selection
biases associated with retrospective data, one-to-one
matching was performed by treatment group, on the vari-
ables of institution, age, sex, tumor size or stage, histologic
differentiation, margin status, and nodal status, resulting in
a total of 496 patients with 248 per treatment arm, either
surgery alone or surgery with adjuvant CRT. There were no
statistically signiﬁcant differences (P[.05) among mat-
ched variables by treatment group (results not shown). As
seen in Fig. 2, matched-pair analysis demonstrated overall
survival was improved with adjuvant CRT versus surgery
alone, with 21.9 vs. 14.3 month median OS and better 2-
year (45.5% vs. 31.4%) and 5-year survival (25.4 vs.
12.2%). Adjuvant CRT decreased risk with RR 0.59 (95%
CI: 0.48–0.72, P\.001). As shown in Fig. 3, adjuvant
CRT compared with surgery alone was associated with
TABLE 1 Baseline characteristics
Observation
only
(n = 509)
Adjuvant
chemoradiation
therapy
(n = 583)
P value
Demographic
Age at surgery (year)
Mean (SD) 68.9 (10.9) 63.7 (3.1) \.001
Median (Range) 70.2 (34–92) 64.7
(29.4–85.6)
Gender
Male, no. (%) 260 (51.1) 316 (54.2) .303
Treatment
Institution
The Johns Hopkins
Hospital
346 (68.0) 272 (46.7) \.001
The Mayo Clinic
Rochester
163 (32.0) 311 (53.3)
Surgery type
Classic PD 196 (38.5) 247 (42.4) .307
Pylorus-preserving PD 279 (54.8) 306 (52.5)
Classic/PP total
pancreatectomy
34 (6.7) 30 (5.1)
Tumor characteristics
Primary tumor
T1 35 (6.9) 33 (5.7) .239
a
T2 79 (15.5) 107 (18.4)
T3 322 (63.3) 335 (57.5)
Unknown 73 (14.3) 108 (18.5)
Nodal status
N0 163 (32.0) 191 (32.8) .795
N? 346 (68.0) 392 (67.2)
Histologic grading
1 12 (2.4) 18 (3.1) .027
2 236 (46.4) 223 (38.3)
3 239 (47.0) 302 (51.8)
4 22 (4.3) 40 (6.9)
Margin
Negative 349 (68.6) 380 (65.2) \.001
Positive 160 (31.4) 203 (34.8)
PD pancreaticoduodenectomy, PP pylorus preserving
a Chi-square compares only non-missing values, with T-stage
unknown among n = 181 JHH patients
984 C. C. Hsu et al.improved survival among both margin negative (RR 0.61,
95% CI: 0.47–0.77, P\.001) and margin positive (RR
0.52, 95% CI: 0.36–0.74, P\.001) disease. Improved
survival with adjuvant CRT was also seen among node
positive disease (RR 0.53, 95% CI: 0.42–0.68, P\.001)
and bordered on statistical signiﬁcance among node nega-
tive disease (RR 0.71, 95% CI: 0.49–1.02, P = .063). A
similarly protective association of adjuvant CRT with
overall survival was seen when stratiﬁed by T-stage and by
tumor differentiation (results not shown).
DISCUSSION
At two high-volume centers for treatment of pancreatic
adenocarcinoma, adjuvant CRTwas signiﬁcantly associated
with improved survival after pancreaticoduodenectomy
compared with surgery alone, regardless of age, tumor size,
TABLE 2 Associations with overall survival and patient, tumor, and treatment characteristics
No. (%) Median surv, months 2-year OS, % 5-year OS, % Univariate RR (95% CI) P value
Demographic
Age (year)
\70 645 (59.1) 19.7 42.1 21.6 1.00
[70 447 (40.9) 17.5 37.1 16.2 1.20 (1.05–1.37) .008
Gender
Female 516 (47.3) 19.5 40.9 18.3 1.00
Male 576 (52.8) 18.5 39.2 20.5 0.98 (0.85–1.12) .730
Treatment
Adjuvant treatment
None 509 (46.6) 15.5 34.6 16.1 1.00
Adjuvant CRT 583 (53.4) 21.1 44.7 22.3 0.73 (0.64–0.84) \.001
Surgery type
Class PD 443 (40.6) 19.7 40.2 22.5 1.00
PPPD 585 (53.6) 18.5 40.2 17.1 1.13 (0.98–1.30) .093
Classic/PP total panc 64 (5.9) 14.9 36.5 18.3 1.19 (0.89–1.60) .228
Tumor characteristics
Primary tumor
a
T1–2 254 (27.9) 26.0 52.0 29.2 1.00
T3 657 (72.1) 17.7 36.5 16.9 1.44 (1.21–1.70) \.001
Nodal status
N- 354 (32.4) 24.8 50.8 26.0 1.00
N? 738 (67.6) 17.4 34.9 15.9 1.46 (1.26–1.69) \.001
Histologic grading
G1/2 489 (44.8) 23.3 49.1 23.5 1.00
G3/4 603 (55.2) 15.7 32.5 16.1 1.44 (1.26–1.65) \.001
Margin
Negative 729 (66.8) 21.0 45.3 22.9 1.00
Positive 363 (33.2) 15.1 29.5 12.7 1.47 (1.28–1.69) \.001
PD pancreaticoduodenectomy, PP pylorus preserving, Total panc total pancreatectomy, N- node negative, N? node positive, Surv survival,
mo months, OS overall survival
a T-stage missing (n = 181) only among JHH patients
1.0
0.8
0.6
0.4
0.2
05
Years
23 14
Survival
Observation only
Chemoradiation
p < 0.001
FIG. 1 Kaplan–Meier plot of overall survival among all 1,092
resected pancreatic adenocarcinoma patients with (yellow line) and
without (blue line) adjuvant chemoradiation therapy (P\.001)
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986 C. C. Hsu et al.margin status, or node status. After adjustment for con-
founders in the propensity score analysis, adjuvant CRT
improved overall survival by approximately 33%
(P\.001), with improved median (15.5 vs. 21.1 months),
2-year (34.6 vs. 44.7%) and 5-year (16.1 vs. 22.3%) overall
survival (P\.001). Furthermore, risk of mortality was
consistently decreased among all risk-stratiﬁed subgroups
(range RR 0.56–0.83) with the addition of adjuvant CRT.
The effects of adjuvant CRT appeared to improve survival
regardless of resection or tumor status, including patients
who were margin positive (adjusted HR 0.57, P\.001),
marginnegative(adjustedHR0.71,P\.001),nodepositive
(adjustedHR0.64,P\.001),ornodenegative(adjustedHR
0.75, P\.037).
For patients with resectable pancreatic adenocarcinoma,
the recommendation of adjuvant CRT in the United States
has been largely based on results of the GITSG, which
demonstrated improved survival for those who underwent
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FIG. 2 Matched-pair analysis: Kaplan–Meier plot of overall survival
of 1:1 matched 496 resected pancreatic adenocarcinoma patients with
(n = 248, yellow line) and without (n = 248, blue line) adjuvant
chemoradiation therapy (P\.001)
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FIG. 3 Stratiﬁed Matched-Pair Analysis. a Kaplan–Meier plot of
overall survival of 1:1 matched resected pancreatic adenocarcinoma
patients with (yellow line) and without (blue line) adjuvant chemo-
radiation therapy, stratiﬁed by margin negative (left, n = 358,
P\.001) and margin positive (right, n = 138, P\.001) status. b
Kaplan–Meier plot of overall survival of 1:1 matched resected
pancreatic adenocarcinoma patients with (yellow line) and without
(blue line) adjuvant chemoradiation therapy, stratiﬁed by node
negative (left, n = 160, P = .063) and node positive (right,
n = 336, P\.001) status
Adjuvant Chemoradiation for Pancreatic Cancer 987adjuvant CRT compared with surgery alone (median OS
10.9 vs. 21.0 months, P = .04).
8 These results were further
conﬁrmed in an additional 30 patients nonrandomly
assigned to adjuvant CRT.
29 However, the GITSG study
has been criticized for its small sample size (n = 43) and
obsolete use of split-course radiation therapy.
In line with GITSG, the EORTC phase III trial found
that compared with those who underwent surgery alone
(n = 54), those who received adjuvant CRT (n = 60) had
an improvement in median overall survival (17.1 vs.
12.6 months), but it only approached statistical signiﬁcance
(P = .099).
8 However, a reanalysis using a one-sided log-
rank test suggested statistical signiﬁcance (P = .049) for 2-
year overall survival.
10
More recently, the ESPAC-1 study suggested that
adjuvant radiation therapy is detrimental to overall survival
compared with surgery alone.
11,12 However, the study’s use
of several concurrent trials, the option for physicians to
deliver background adjuvant therapy prior to randomiza-
tion, a complex 2 9 2 factorial design, lack of central
review, and the lack of radiation-ﬁeld design parameters
are a few of the criticisms that question the validity of the
ﬁndings of ESPAC-1.
13–18 Though the authors suggest the
detriment of adjuvant CRT, the OS results for this treat-
ment arm in the ESPAC-1 study are much poorer than and
inconsistent with previous ﬁndings from other randomized
trials.
8,15,24 This collaborative study pools data from the
Johns Hopkins Hospital and Mayo Clinic, Rochester, and
demonstrates that adjuvant CRT is not detrimental com-
pared with surgery alone and appears to offer signiﬁcant
beneﬁt for overall survival.
The results in the current study are consistent with the
GITSG and EORTC randomized trials and also conﬁrm the
results of several single institution studies as well as a
national surveillance study.
3,21–23 Additionally, adjuvant
CRT outcomes in the current study are similar to a recent
U.S. Gastrointestinal Intergroup phase III randomized trial
evaluating adjuvant CRT plus gemcitabine versus ﬂuoro-
uracil systemic chemotherapy, with median OS of 20.5 vs.
16.9 months, respectively.
24
In the current analysis, patients across all risk groups
demonstrated improved survival with adjuvant CRT,
compared with surgery alone. In no subgroup was there
evidence that adjuvant CRT was detrimental. However,
there are several limitations of our study. Despite its size
combined from the experience of two institutions, we are
unable to answer the question of whether adjuvant CRT
confers beneﬁt beyond adjuvant chemotherapy. Addition-
ally, our ﬁndings are limited by the fact that they are
retrospective. Though we attempt to deal with biases
associated with treatment selection with both the propen-
sity score and matched-pair analyses, we are limited by the
fact that data on performance status, length of hospital stay,
comorbid diseases, and postoperative recovery were not
available for all patients. These factors may play a signif-
icant role in the decision for patients to undergo adjuvant
CRT. Additionally, data on surgical complications were
only available for the Johns Hopkins patients, and these
data were not used as criteria for the matched-pair analysis.
It is not possible given these limitations to completely
remove the inﬂuence of selection bias from our analyses.
Furthermore, we do not have data on local recurrence rates
since many did not have a prospective plan for follow-up
imaging. Nevertheless, we attempt to deal with these issues
in as comprehensive a fashion as possible, given our data,
and demonstrate the consistency of the beneﬁt of adjuvant
CRT on overall survival across risk groups. Furthermore,
this study population from two high-volume treatment
centers for pancreatic adenocarcinoma, with sufﬁcient
surgical, medical oncology, and radiation oncology expe-
rience, allowed performance of stratiﬁed analyses and more
sophisticated statistical analyses that require larger num-
bers of patients.
The current collaborative analyses attempted to account
for treatment selection biases associated with retrospective
data through not only propensity score analyses but also
matched-pair analyses. Both methods conﬁrmed the asso-
ciation with improved survival of adjuvant CRT over
surgery alone (matched-pair HR 0.59, 95% CI: 0.48–0.72,
P\.001).
In summary, this collaborative study from the Johns
Hopkins Hospital and Mayo Clinic strongly supports the
use of adjuvant CRT in patients with resected pancreatic
adenocarcinoma. The beneﬁt is consistent across all high-
risk groups, and the status of resection should not alter
adjuvant CRT recommendations. These current results,
combining the experience of two high-volume institutions,
call into question the results of ESPAC-1, which suggested
a detrimental effect of adjuvant CRT.
Future studies are needed that focus on the sequencing
of treatment modalities and explore aggressive systemic
therapies. With regard to sequencing of trimodality treat-
ment, preoperative CRT may be preferable to postoperative
CRT for patients in whom R1 and R2 resections would be
expected based on preoperative imaging (i.e., borderline or
unresectable disease) in an attempt to prevent local and
distant recurrence. Neoadjuvant treatment may be prefer-
able as it is unlikely that any adjuvant therapy, including
radiation, can successfully sterilize macroscopic residual
disease. Some institutions even prefer preoperative CRT
for resectable cancers, although it is still unclear which
patients are more likely to beneﬁt from preoperative
treatment as opposed to upfront surgical resection.
30,31
With regard to the use of more effective systemic
therapy, results now exist from at least two phase III trials
that demonstrate a beneﬁt with adjuvant chemotherapy
988 C. C. Hsu et al.over surgery alone for patients with resected pancreas
cancer (adjuvant 5FU-Leucovorin in the ESPAC-1 trial and
adjuvant gemcitabine in the CONKO-001 trial).
11,12,32
However, it is unclear whether adjuvant chemotherapy
alone has any impact on local recurrence. Although adju-
vant CRT appears to improve both local control and
survival when compared with surgery alone in select phase
II and phase III trials, OS is still inadequate in view of the
high rate of hematologic and peritoneal relapse. Accord-
ingly, more effective systemic therapy combined with the
most effective local–regional treatment (surgery plus
adjuvant CRT) will be needed to achieve optimal survival
results.
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